CXorf22 Inhibitors
Inhibitors of CXorf22 target various signaling pathways to indirectly reduce its functional activity. Compounds that interfere with the MAPK pathway, which includes the MEK1/2 and ERK components, have a downstream impact that can lead to the suppression of CXorf22 activity. This is due to the essential role of the MAPK pathway in the activation and stabilization of proteins that rely on this signaling cascade. Similarly, by inhibiting tyrosine kinases within the RAF/MEK/ERK pathway, some inhibitors exert a broader spectrum of action, potentially dampening the functional activity of CXorf22 by curtailing the pathway's signaling output. Furthermore, inhibitors that selectively target JNK or p38 MAPK within the MAPK pathway also contribute to the decrease in activity of proteins that are modulated by these specific kinase signaling branches, which includes CXorf22 if it functions downstream of these kinases.
Other inhibitors aim at the PI3K/Akt/mTOR pathway, which is crucial for cell growth andproliferation. PI3K inhibitors, for instance, attenuate Akt signaling, subsequently affecting downstream proteins that are regulated by this pathway, which may encompass CXorf22. Additionally, mTOR inhibitors, such as those structurally related to rapamycin, can lead to a reduction in protein synthesis and cell proliferation, thereby decreasing the activity of proteins that are downstream of mTOR signaling, including CXorf22. Disruption of the ubiquitin-proteasome system through proteasome inhibitors also results in the altered signaling dynamics, which could potentially reduce CXorf22 activity if it is subject to regulation by proteasomal degradation.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Selumetinib | 606143-52-6 | sc-364613 sc-364613A sc-364613B sc-364613C sc-364613D | 5 mg 10 mg 100 mg 500 mg 1 g | $29.00 $82.00 $420.00 $1897.00 $3021.00 | 5 | |
This compound is a MEK1/2 inhibitor that interferes with the mitogen-activated protein kinase (MAPK) pathway. CXorf22 function is downregulated due to the suppression of downstream signaling that is crucial for the activation and stabilization of proteins dependent on this pathway. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A phosphoinositide 3-kinase (PI3K) inhibitor that disrupts the PI3K/Akt signaling pathway. This inhibition results in a downstream effect that reduces the activity of certain proteins modulated by Akt, potentially including CXorf22, if it is a downstream effector in this pathway. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
A tyrosine kinase inhibitor that blocks several enzymes, including those in the RAF/MEK/ERK pathway. By inhibiting this pathway, it indirectly decreases the activity of proteins that are regulated as part of this signaling cascade, including CXorf22. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
This compound is a selective inhibitor of both MEK1 and MEK2, which are part of the MAPK pathway. Inhibition of MEK leads to reduced ERK phosphorylation and activity, which could decrease CXorf22 activity if it is regulated by the ERK pathway. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor that blocks the mTORC1 complex, leading to a decrease in protein synthesis and cell proliferation. This inhibition could reduce the functional activity of proteins that are downstream of mTOR signaling, potentially including CXorf22. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
An irreversible inhibitor of PI3K that impedes the PI3K/Akt/mTOR pathway. This culminates in a decrease in the activity of proteins regulated by mTOR, potentially affecting CXorf22 as a downstream target. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
An inhibitor of MEK that blocks the activation of MAPK/ERK. By inhibiting this pathway, the compound indirectly reduces the functional activity of proteins that are regulated by ERK signaling, potentially including CXorf22. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
A selective inhibitor of c-Jun N-terminal kinase (JNK), which is part of the MAPK pathway. Inhibition of JNK can lead to decreased activity of proteins regulated by JNK signaling, which may include CXorf22 if it is a downstream target. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
A specific inhibitor of p38 MAPK, leading to the inhibition of p38-dependent signaling pathways. This could result in decreased functional activity of proteins that are modulated by p38 MAPK, including CXorf22 if it is a downstream component. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
A proteasome inhibitor that impedes the degradation of proteins regulated by the ubiquitin-proteasome system. This inhibition can lead to altered signaling dynamics and potentially reduce the activity of CXorf22 if it is regulated through proteasomal degradation. | ||||||